$TYRA
Tyra Biosciences, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023017875 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $0.00 $3.926M $5.189M
YoY Change -100.0% -24.34% 653.12%
% of Gross Profit
Research & Development $12.16M $10.41M $9.645M
YoY Change 0.95% 7.91% 173.85%
% of Gross Profit
Depreciation & Amortization $100.0K $83.00K $64.00K
YoY Change -99.86% 29.69% 190.91%
% of Gross Profit
Operating Expenses $16.01M $14.33M $14.83M
YoY Change 3.8% -3.37% 252.27%
Operating Profit -$16.01M -$14.33M -$14.83M
YoY Change 3.8% -3.37% 252.27%
Interest Expense $2.763M $2.455M $18.00K
YoY Change 698.55% 13538.89% 800.0%
% of Operating Profit
Other Income/Expense, Net $2.742M $2.454M $8.000K
YoY Change 723.42% 30575.0% 300.0%
Pretax Income -$13.27M -$11.88M -$14.83M
YoY Change -12.08% -19.87% 252.25%
Income Tax
% Of Pretax Income
Net Earnings -$13.27M -$11.88M -$14.83M
YoY Change -12.08% -19.87% 252.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.31 -$0.28 -$0.36
Diluted Earnings Per Share -$0.31 -$0.28 -$356.8K
COMMON SHARES
Basic Shares Outstanding 42.56M 42.44M 41.60M
Diluted Shares Outstanding 42.59M 42.39M 41.55M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $232.4M $241.7M $292.5M
YoY Change -15.52% -17.37% 107.98%
Cash & Equivalents $232.4M $241.7M $292.5M
Short-Term Investments
Other Short-Term Assets $8.333M $5.008M $1.526M
YoY Change 280.16% 228.18% 703.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $240.7M $246.7M $294.0M
YoY Change -13.18% -16.09% 108.78%
LONG-TERM ASSETS
Property, Plant & Equipment $1.054M $1.048M $1.008M
YoY Change -12.24% 3.97% 115.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $866.0K $3.874M $362.0K
YoY Change -82.96% 970.17% -29.57%
Total Long-Term Assets $9.266M $8.346M $4.946M
YoY Change -5.63% 68.74% 404.18%
TOTAL ASSETS
Total Short-Term Assets $240.7M $246.7M $294.0M
Total Long-Term Assets $9.266M $8.346M $4.946M
Total Assets $250.0M $255.1M $299.0M
YoY Change -12.92% -14.69% 110.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.440M $1.280M $1.356M
YoY Change -38.54% -5.6% 61.24%
Accrued Expenses $3.965M $2.402M $3.545M
YoY Change 27.41% -32.24% 410.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.405M $3.682M $4.901M
YoY Change -0.92% -24.87% 219.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $108.0K $139.0K $303.0K
YoY Change -58.62% -54.13% -41.95%
Total Long-Term Liabilities $108.0K $139.0K $303.0K
YoY Change -58.62% -54.13% -41.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.405M $3.682M $4.901M
Total Long-Term Liabilities $108.0K $139.0K $303.0K
Total Liabilities $11.44M $6.265M $7.787M
YoY Change 38.42% -19.55% 278.56%
SHAREHOLDERS EQUITY
Retained Earnings -$120.8M -$107.6M -$55.20M
YoY Change 71.92% 94.89%
Common Stock $359.4M $356.4M $346.4M
YoY Change 2.94% 2.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $238.6M $248.8M $291.2M
YoY Change
Total Liabilities & Shareholders Equity $250.0M $255.1M $299.0M
YoY Change -12.92% -14.69% 110.83%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$13.27M -$11.88M -$14.83M
YoY Change -12.08% -19.87% 252.25%
Depreciation, Depletion And Amortization $100.0K $83.00K $64.00K
YoY Change -99.86% 29.69% 190.91%
Cash From Operating Activities -$9.615M -$9.847M -$8.925M
YoY Change -43.99% 10.33% 90.79%
INVESTING ACTIVITIES
Capital Expenditures $43.00K $41.00K $239.0K
YoY Change -117.13% -82.85% 298.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$43.00K -$41.00K -$239.0K
YoY Change -82.87% -82.85% 298.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 370.0K 376.0K 238.0K
YoY Change 1270.37% 57.98% -99.82%
NET CHANGE
Cash From Operating Activities -9.615M -9.847M -8.925M
Cash From Investing Activities -43.00K -41.00K -239.0K
Cash From Financing Activities 370.0K 376.0K 238.0K
Net Change In Cash -9.288M -9.512M -8.926M
YoY Change -46.6% 6.57% -107.12%
FREE CASH FLOW
Cash From Operating Activities -$9.615M -$9.847M -$8.925M
Capital Expenditures $43.00K $41.00K $239.0K
Free Cash Flow -$9.658M -$9.888M -$9.164M
YoY Change -42.91% 7.9% 93.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42561733
CY2023Q1 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
241701000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251213000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5008000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6075000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
246709000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
257288000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1048000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1077000
CY2023Q1 tyra Right Of Use Asset
RightOfUseAsset
2424000
CY2022Q4 tyra Right Of Use Asset
RightOfUseAsset
2466000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3874000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4350000
CY2023Q1 us-gaap Assets
Assets
255055000
CY2022Q4 us-gaap Assets
Assets
266181000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1280000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1145000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
144000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
140000
CY2023Q1 tyra Accrued And Other Related Parties
AccruedAndOtherRelatedParties
0
CY2022Q4 tyra Accrued And Other Related Parties
AccruedAndOtherRelatedParties
59000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2258000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4416000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3682000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5701000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2444000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2482000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
139000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
169000
CY2023Q1 us-gaap Liabilities
Liabilities
6265000
CY2022Q4 us-gaap Liabilities
Liabilities
8352000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42762501
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42634459
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42535374
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42353550
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
356362000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
353521000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107576000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95696000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
248790000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
255055000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
266181000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10408000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9645000
CY2023Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
CY2022Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
210000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3926000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5189000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
14334000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
14834000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14334000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14834000
CY2023Q1 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
2455000
CY2022Q1 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
18000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
10000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2454000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14826000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001863127
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40800
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2023Q1 dei City Area Code
CityAreaCode
619
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
728-4760
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
TYRA
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42394623
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42394623
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41551713
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41551713
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
238000
CY2022Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
63000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3972000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14826000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
291184000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2023Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
376000
CY2023Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
32000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2433000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
248790000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14826000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2433000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3972000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1530000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-299000
CY2023Q1 tyra Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions
AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions
0
CY2022Q1 tyra Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions
AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions
22000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2022000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1560000
CY2023Q1 tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
9000
CY2022Q1 tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
4000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9847000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8925000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
239000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-239000
CY2023Q1 tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
376000
CY2022Q1 tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
238000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
376000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
238000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9512000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8926000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
302425000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
242701000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293499000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
241701000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292499000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
242701000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293499000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1547000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-02
CY2022Q4 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
440000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2258000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4416000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1000000.0
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1000000.0
CY2023Q1 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-3274
CY2022Q1 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-454163
CY2023Q1 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-292870
CY2022Q1 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-579781
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42394623
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42394623
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41551713
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41551713
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1592000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1538000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
544000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
461000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1048000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1077000
CY2023Q1 us-gaap Depreciation
Depreciation
83000
CY2022Q1 us-gaap Depreciation
Depreciation
64000
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
863000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2854000
CY2023Q1 tyra Accrued Research And Development
AccruedResearchAndDevelopment
986000
CY2022Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1028000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
79000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2023Q1 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
330000
CY2023Q1 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
6126093
CY2022Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
5890869
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13418081
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10989684
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5890869
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.91
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13492000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
541300
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.55
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
97227
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
208849
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.68
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6126093
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.94
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
55897000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1975304
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.06
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
20377000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6126093
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.94
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
55897000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2433000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3972000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
24500000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2023Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
100000
CY2022Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
200000
CY2023Q1 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
225581
CY2022Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
277081
CY2023Q1 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
100000
CY2022Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
200000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14826000
CY2023Q1 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42690767
CY2022Q1 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42585657
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6354849
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4712764
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
83000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
73000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
22000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
20000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
14000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
16000
CY2023Q1 us-gaap Lease Cost
LeaseCost
119000
CY2022Q1 us-gaap Lease Cost
LeaseCost
109000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
225000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
309000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
318000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
328000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
337000
CY2023Q1 tyra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2044000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3561000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
973000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2588000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
144000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2444000
CY2023Q1 tyra Minimum Lease Payments For Leases Not Yet Commenced
MinimumLeasePaymentsForLeasesNotYetCommenced
5500000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M

Files In Submission

Name View Source Status
tyra-20230331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
0000950170-23-017875-index-headers.html Edgar Link pending
0000950170-23-017875-index.html Edgar Link pending
0000950170-23-017875.txt Edgar Link pending
0000950170-23-017875-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20230331.htm Edgar Link pending
tyra-20230331.xsd Edgar Link pending
tyra-ex31_1.htm Edgar Link pending
tyra-20230331_cal.xml Edgar Link unprocessable
tyra-20230331_def.xml Edgar Link unprocessable
tyra-20230331_lab.xml Edgar Link unprocessable
tyra-20230331_htm.xml Edgar Link completed
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending